Controversies in anesthetic management of liver transplantation  by Manley, Joseph L. et al.
REVIEW ARTICLE
Controversies in anesthetic management of liver transplantation
JOSEPH L. MANLEY1, JEFFERY S. PLOTKIN1, JOHN YOSAITIS1 & DAVID J. PLEVAK2
1Georgetown Transplant Institute, Washington, DC, USA and 2Mayo Clinic, Rochester, MN, USA
Abstract
Controversies in the anesthetic management of liver transplantation (OLT) include the exclusion of patients with pulmonary
hypertension, intracranial pressure monitoring in patients with fulminant hepatic failure, preoperative screening for coronary
artery disease, perioperative use of anticoagulant medications, and early extubation after surgery. This manuscript discusses
these controversies from the perspective of two institutions that possess a long tradition of providing liver transplantations for
patients with end-stage liver disease.
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Introduction
Although results of orthotopic liver transplantation
(OLT) have steadily improved, many questions
regarding best practices persist. A major objective of
the Liver Anesthesiology and Critical Care Symposium
of the Sixth World Congress of the International
Hepato-Pancreato-Biliary Association (June, 2004) is
to explore data and opinions regarding such questions.
With that in mind, the authors will moderate a
discussion at the Symposium with the intention of
highlighting and illuminating some controversial areas
in the realm of anesthetic management of OLT. Likely
topics of discussion include anticoagulation, pulmon-
ary hypertension, preoperative cardiac evaluation,
early extubation and fulminant hepatic failure. In this
paper, we intend to explore these topics and offer some
data and opinions regarding practices at our institu-
tions. Our discussion is primarily focused on peri-
operative management of adult OLT recipients.
Anticoagulation
Bleeding and thrombosis are two important compli-
cations of OLT. Acute thrombotic complications
following OLT (e.g. hepatic artery thrombosis 9%,
portal vein thrombosis 3%–13%) are associated with
increased morbidity and mortality [1,2]. Given the
tendency toward bleeding, anticoagulation is not given
routinely to these patients. While a hypercoagulable
state is occasionally found following reperfusion of the
liver (as demonstrated by thromboelastograph (TEG)
or other point-of-care test of whole-blood coagulation)
the role of prophylactic anticoagulation is not defined
by current literature.
At Georgetown Transplant Institute (GTI) we rarely
anticoagulate OLT recipients during the perioperative
period. Generally, heparin is only given after an
episode of thrombosis. Heparin is our preferred
anticoagulant because of reversibility, short duration
and ease of titration. Anticoagulation would only be
recommended in the absence of significant bleeding
and in the absence of laboratory evidence of coagulo-
pathy. At Mayo Clinic low molecular weight heparin is
sometimes given after surgery.
In most OLT recipients, we avoid giving any pro-
coagulants (except FFP) prior to unclamping the
hepatic artery. Even after unclamping, systemic pro-
coagulants are often withheld unless the diagnosis of
coagulopathy is supported by both laboratory evidence
(usually TEG or platelet count) and clinical evidence
(e.g. diffuse oozing and lack of clot in the field). The
choice of pro-coagulants (usually FFP, platelet
concentrate, aminocaproic acid or protamine) is
guided by preoperative platelet count, estimated blood
loss, and intraoperative TEG. Other centers have used
alternate pro-coagulants such as desmopressin injec-
tion (DDAVP) and aprotinin (Trasylol).
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In some cases of diffuse oozing not responsive to the
therapy listed above, intravenous recombinant acti-
vated factor seven (rFVIIa, NovoSeven) has been an
effective hemostatic agent [3].
All decisions regarding the use of anticoagulants and
pro-coagulants are discussed with the surgeon before-
hand (except FFP which we often give without
discussion).
Pulmonary hypertension
Although definitions of pulmonary hypertension vary,
portopulmonary hypertension (PPHTN) is an ele-
vation in pulmonary artery (PA) pressures evolving in
the presence of portal hypertension and in the absence
of any other known causes of pulmonary hypertension.
Severe PPHTN was considered a contraindication
to OLT prior to the demonstration that a subset of
these patients responded favorably to epoprostanol
(Flolan) [4].
Our approach to PPHTN at GTI follows the algo-
rithm of Kuo et al: assuming no other contraindications
to OLT are present (and left ventricular function is
preserved on dobutamine stress echocardiogram
(DSE)), patients suspected of having severe PPHTN
(usually based on echocardiographic estimate and
respiratory alkalosis present on blood gas) undergo
right heart catheterization (PAC). If mean PA pressure
is 440 mmHg, epoprostanol is given by continuous
infusion with an implantable pump. PAC is repeated at
3–6 month intervals. When mean PA pressure is
540 mmHg, a DSE is obtained with the PAC in situ.
If left and right ventricular function are adequate at rest
and during stress, an intravenous fluid bolus is admi-
nistered (1L normal saline over 10 minutes). If mean
PA pressure remains 540 mmHg and biventricular
function is preserved, the patient is considered a
candidate for OLT. At Mayo Clinic the approach is
similar, however, pulmonary vascular resistance and
other factors influence timing of OLT if mean PA
pressure is 35–50 mmHg.
Echocardiographic estimates of PA systolic pressure
are based on the modified Bernoulli equation which
allows one to calculate the pressure difference (during
systole) between the right atrium and right ventricle
from the velocity of the regurgitant jet across the
tricuspid valve. This difference is added to the central
venous pressure (whether measured or estimated).
This method depends on the presence of tricuspid
regurgitation and the ability to direct continuous
wave Doppler across the valve parallel (or nearly so) to
the direction of blood flow. The method also assumes
that there is no gradient (during systole) between the
RV and the PA. Use of estimated (rather than
measured) CVP increases the degree of uncertainty in
the result.
We place PA catheters in all adult OLT recipients.
Transesophageal echocardiogram (TEE) is placed
selectively. These monitors have special value in the
setting of pulmonary hypertension.
Although PAC and TEE use are not mutually
exclusive, it is worthwhile to briefly mention their
relative merits. A PAC has some advantages over a
TEE in perioperative management of pulmonary
hypertension: The PAC will accurately measure PA
pressures which must be measured in order to deter-
mine if the patient is a candidate for transplant. The
PAC can be used as a continuous monitor in the
operating room (OR) and intensive care unit (ICU)
whereas the TEE can not be used as a continuous
monitor. Determination of cardiac output and
systemic vascular resistance are far easier with a PAC
than with TEE. Also, the PAC can be used for deter-
minations of mixed venous oxygen saturation and
pulmonary vascular resistance.
A TEE should be inserted in the setting of unex-
pectedly high PA pressures both for determining the
etiology of the pulmonary hypertension (e.g. pulmon-
ary thromboembolus) and following the response to
therapy (e.g. changes in left ventricular end-diastolic
volume after furosemide). During OLT (and the
immediate postoperative interval), TEE is especially
useful when significant changes in hemodynamics are
difficult to explain (e.g. severe hypotension refractory
to pressors when filling pressures are roughly normal
and labs and electrocardiogram are normal) [5]. The
presence of esophageal varices does not absolutely
contraindicate use of TEE.
If mean PA pressure is440 mmHg (or greater than
two thirds of mean arterial pressure (MAP)) when a
liver becomes available, one must determine if the
pulmonary hypertension can be reversed prior to
proceeding with OLT; a fixed high PA pressure is
associated with poor outcome and, in such cases, the
available liver should be released to the next patient on
the list. If a patient presents to the operating room for
OLT with newly diagnosed or breakthrough pulmon-
ary hypertension, the pulmonary hypertension ought
to be treated before a decision is made whether to
cancel the case. An attempt can be made to bring PA
pressure down acutely with oxygen, hyperventilation
and anesthesia (fentanyl/isoflurane). If PA occlusive
pressure (wedge) is high, furosemide might be given
especially if systemic pressure and cardiac output are
normal or high. If the patient is on epoprostanol on
arrival to the OR, this is continued. Milrinone or
inamrinone may be useful in the setting of right or left
ventricular failure.
Preoperative cardiac evaluation
Coronary artery disease (CAD) is found in 27% of
patients over 50 years age referred for liver transplant
evaluation [6]. DSE has been shown to be sensitive
and specific for diagnosing CAD in patients with
multiple cardiac risk factors who have been referred for
OLT [7].
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Early extubation
The frequency of very early extubation (i.e. tracheal
extubation at the conclusion of surgery prior to leaving
the OR) in OLT recipients varies widely among
transplant centers [8,9]. Immediate extubation
following OLT has several potential benefits. These
include decreased cost, improved patient comfort and
satisfaction, decreased ICU and hospital length of stay,
early neurological evaluation and improved pulmonary
toilet with decreased incidence of ventilator associated
pneumonia. Early extubation also carries risks. These
include postoperative ventilatory failure with impaired
oxygen delivery to the newly grafted liver. Another
possible disadvantage of early extubation is the need
for re-intubation if the patient returns to the OR (for
early complications such as bleeding, bile leak,
thrombosis, or re-transplantation).
Several studies have explored these issues. For
example, Mandell et al. studied 173 OLT recipients
retrospectively: 41 were tracheally extubated at the end
of surgery; 2 of these had to be re-intubated within
30 minutes due to respiratory failure. Both patients
were successfully extubated after another 12–14 hours
of ventilatory support. The authors found that early
extubation was associated with an average savings of
$2709. They concluded that immediate tracheal
extubation following OLT is safe and cost-effective in
selected patients. In this study, criteria associated with
successful immediate tracheal extubation were lesser
disease severity (i.e. old UNOS status 3 or 4), absence
of encephalopathy or co-existing disease, age 550
years, good graft function, RBC transfusion 510 U,
alveolar-arterial oxygen gradient5150 mmHg and no
vasoactive support at end of surgery. Although early
extubation has been successful in many patients,
optimal selection criteria and timing for early extuba-
tion are not defined by the current literature.
Furthermore, results from a single center may not be
generalizable due to differences in staffing and other
resources.
Fulminant hepatic failure and coma
Fulminant hepatic failure is frequently associated with
brain edema and concomitant intracranial hyperten-
sion [10]. Sustained elevation of intracranial pressure
(cerebral perfusion pressure540 mmHg for 2 hours)
is associated with 100% mortality [11]. At GTI we
follow an intracranial pressure (ICP) management
protocol similar to that outlined by Hoofnagle et al.: an
epidural ICP monitor is placed at the onset of stage III
coma (marked confusion, sleeping but arousable) after
baseline head CT scan and after coagulopathy is
corrected (see below). Hyperventilation, diuretics, fluid
restriction, hemodialysis, head elevation, intravenous
anesthesia (usually propofol or fentanyl) and muscle
relaxants are administered as needed to keep ICP
below 20 mmHg. Hypothermia (33–35C) is induced
(with surface cooling) if ICP remains high. Cerebral
perfusion pressure (CPP=MAP7ICP) is maintained
above 50 mmHg. If a sustained decrease in CPP (as
defined above) occurs, the patient is not considered a
suitable candidate for liver transplant. At Mayo Clinic
an intraparenchymal ICP monitor is preferred.
As mentioned above, significant coagulopathy
(INR 42 seconds or platelet count 5100 k/mcL) is
corrected prior to placement of the ICP monitor. If
INR fails to correct with FFP, rFVIIa 80 mcg/kg is
administered.
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